These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15916838)

  • 21. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan as a novel nasal delivery system for vaccines.
    Illum L; Jabbal-Gill I; Hinchcliffe M; Fisher AN; Davis SS
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):81-96. PubMed ID: 11516781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of inactivated trivalent influenza vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Shah SI; Caprio M; Hendricks-Munoz K
    Pediatrics; 2007 Sep; 120(3):e617-21. PubMed ID: 17766502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
    Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
    Hagenaars N; Mania M; de Jong P; Que I; Nieuwland R; Slütter B; Glansbeek H; Heldens J; van den Bosch H; Löwik C; Kaijzel E; Mastrobattista E; Jiskoot W
    J Control Release; 2010 May; 144(1):17-24. PubMed ID: 20100528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA; Jabbal-Gill I; Illum L; Pizza M; Rappuoli R; Podda A; Lewis DJ; Mills KH
    Vaccine; 2004 Feb; 22(8):909-14. PubMed ID: 15161067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
    Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial.
    Scharpé J; Peetermans WE; Vanwalleghem J; Maes B; Bammens B; Claes K; Osterhaus AD; Vanrenterghem Y; Evenepoel P
    Am J Kidney Dis; 2009 Jul; 54(1):77-85. PubMed ID: 19339089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients.
    Tanzi E; Amendola A; Pariani E; Zappa A; Colzani D; Logias F; Perego A; Zanetti AR
    J Med Virol; 2007 Aug; 79(8):1176-9. PubMed ID: 17596830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
    Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
    Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The response in hemagglutinoinhibiting antibodies following influenza vaccination of HIV-infected children.
    Ioniţă E; Gherghina I; Lupulescu E; Alexandrescu V; Tabra ME
    Roum Arch Microbiol Immunol; 1998; 57(1):53-7. PubMed ID: 9745335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.